NASDAQ:KZIA Kazia Therapeutics (KZIA) Stock Price, News & Analysis $4.66 -0.54 (-10.38%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Kazia Therapeutics Stock (NASDAQ:KZIA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kazia Therapeutics alerts:Sign Up Key Stats Today's Range$4.48▼$5.2150-Day Range$3.20▼$5.7952-Week Range$1.87▼$15.80Volume249,233 shsAverage Volume453,490 shsMarket Capitalization$122.84 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingBuy Company OverviewKazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.Read More… Election warning coming true… (Ad)If you missed it, my emergency election broadcast is now available - watch it before it's too late.Click here to watch it now. Kazia Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks60th Percentile Overall ScoreKZIA MarketRank™: Kazia Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 489th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKazia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKazia Therapeutics has received no research coverage in the past 90 days.Read more about Kazia Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Kazia Therapeutics are expected to grow in the coming year, from ($0.40) to ($0.33) per share.Price to Book Value per Share RatioKazia Therapeutics has a P/B Ratio of 9.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.62% of the outstanding shares of Kazia Therapeutics have been sold short.Short Interest Ratio / Days to CoverKazia Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kazia Therapeutics has recently decreased by 47.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKazia Therapeutics does not currently pay a dividend.Dividend GrowthKazia Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.62% of the outstanding shares of Kazia Therapeutics have been sold short.Short Interest Ratio / Days to CoverKazia Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kazia Therapeutics has recently decreased by 47.37%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment0.96 News SentimentKazia Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kazia Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for KZIA on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Kazia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kazia Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Kazia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 30.89% of the stock of Kazia Therapeutics is held by institutions.Read more about Kazia Therapeutics' insider trading history. Receive KZIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KZIA Stock News HeadlinesKazia Therapeutics trading halted, news pendingOctober 26 at 12:41 AM | markets.businessinsider.comKazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq ListingOctober 16, 2024 | finance.yahoo.comProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.October 29, 2024 | Weiss Ratings (Ad)Kazia Therapeutics (NASDAQ:KZIA) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comKazia Announces Positive Phase 1 Data For Concurrent Paxalisib, Radiation Therapy In Brain TumorOctober 3, 2024 | markets.businessinsider.comKazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual MeetingOctober 2, 2024 | prnewswire.comKazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research SymposiumSeptember 23, 2024 | prnewswire.comKAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFERSeptember 12, 2024 | prnewswire.comSee More Headlines KZIA Stock Analysis - Frequently Asked Questions How have KZIA shares performed this year? Kazia Therapeutics' stock was trading at $4.3950 at the start of the year. Since then, KZIA shares have increased by 6.0% and is now trading at $4.66. View the best growth stocks for 2024 here. When did Kazia Therapeutics' stock split? Kazia Therapeutics's stock reverse split before market open on Monday, October 28th 2024. The 1-10 reverse split was announced on Tuesday, October 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Kazia Therapeutics? Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kazia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kazia Therapeutics investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Today10/28/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KZIA CUSIPN/A CIK1075880 Webwww.kaziatherapeutics.com Phone(129) 472-4101Fax61-2-9476-0388Employees12Year FoundedN/APrice Target and Rating Average Stock Price Target$20.00 High Stock Price Target$20.00 Low Stock Price Target$20.00 Potential Upside/Downside+329.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$20,000.00 Price / Sales6,141.88 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book9.32Miscellaneous Outstanding Shares26,360,000Free Float26,098,000Market Cap$122.84 million OptionableOptionable Beta2.11 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:KZIA) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Kazia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.